h.brandt
TL2 Moderator · Bergen
Contributes reviews on supplier material. Based in Bergen.
Joined 15 May 2025 · last posted 6d
78 posts, newest first. Showing up to 150.
-
Splitting an overlong document into two Replied, post #34 · Documentation › Wiki requests · 22 Jul 2026 · 0 likes Format suggestions: if you think a maintained page could be clearer in its presentation (different section structure, different examples, added graphics) suggest the…
-
Journal club: what we got wrong in an earlier session Replied, post #88 · Evidence › Journal club · 16 Jul 2026 · 5 likes Worth separating two things that post #84 runs together. SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is not…
-
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #106 · Devices › Syringes & needles · 14 Jul 2026 · 1 like Needle gauge: smaller numbers (30G) are finer and less painful. Larger numbers (25G) are courser. For subcutaneous injection, 27-30G is typical. Finer needles take…
-
Why chargeback is not the safety net people assume Replied, post #23 · Sourcing › Payments · 6 Jul 2026 · 1 like No payment facilitation: this site does not handle payments and does not connect buyers and sellers for the purpose of payment. We discuss logistics and documentation…
-
How shortages have affected compounding permissions Replied, post #11 · Access › Shortages · 2 Jul 2026 · 17 likes post #10 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Reading order for a first week here, and what to skip until later — what changed since Started this topic · Start Here › Welcome · 29 Jun 2026 · 0 likes Reading order for a first week here, and what to skip until later — what changed since Writing it up because I had to work it out twice and would rather nobody else…
-
Prescription requirements and telehealth models — a second dataset Replied, post #82 · Sourcing › Regulatory · 27 Jun 2026 · 10 likes Coming back to post #80, because the follow-up matters more than the original answer. Approval versus licensing: a compound can be approved for a specific indication in…
-
About the Receptor biology category Replied, post #7 · Pharmacology › Receptor biology · 27 Jun 2026 · 28 likes Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide…
-
Submitting a sample: the process end to end Replied, post #40 · Sourcing › Independent verification · 26 Jun 2026 · 0 likes Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #43 · Compounds › Repair & healing peptides · 16 Jun 2026 · 8 likes Picking up post #40: that is the part I would want checked first. BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and…
-
Naming conventions for research peptides and the confusion they cause Replied, post #14 · Compounds › Other compounds · 11 Jun 2026 · 0 likes This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits…
-
Reading a trial's population section before its results Replied, post #82 · Evidence › Trials · 3 Jun 2026 · 28 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #21 · Compounds › Secretagogues & GH axis · 2 Jun 2026 · 2 likes Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or…
-
Trust level 3 requirements: a clarification — does this still hold? Replied, post #53 · Meta › Announcements · 26 May 2026 · 0 likes Coming back to post #51, because the follow-up matters more than the original answer. Feedback to announcements: if you have feedback on an announced change (not a…
-
Second pass at: Why chargeback is not the safety net people assume Replied, post #3 · marked as the solution · Sourcing › Payments · 11 May 2026 · 10 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #4 · Compounds › Secretagogues & GH axis · 10 May 2026 · 0 likes On post #2 — agreed on the reasoning, with one qualification. Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large…
-
Blind submission and why it changes minds — the long version Replied, post #58 · Sourcing › Independent verification · 5 May 2026 · 12 likes How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity, labelling, shipping. Following their instructions exactly…
-
Micro-titration: a disputed topic, argued properly Replied, post #67 · Practice › Dosing & titration · 29 Apr 2026 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #31 · Practice › Interactions · 23 Apr 2026 · 1 like For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Choosing which test to pay for, given a fixed budget Replied, post #64 · Sourcing › Independent verification · 11 Apr 2026 · 12 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…
-
Grapefruit: why this class is not the class that cares Replied, post #130 · Practice › Interactions · 7 Apr 2026 · 0 likes Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as…
-
Bug report: the reconstitution calculator and a rounding edge case Replied, post #40 · Data & Tools › Calculators · 6 Apr 2026 · 0 likes Worth separating two things that post #36 runs together. Why calculators are not medical advice: they do arithmetic. Medical decisions are not arithmetic. A calculator…
-
Residual solvents and scavengers: what is looked for — what changed since Replied, post #12 · Analytics › Impurities & related substances · 2 Mar 2026 · 25 likes I read post #10 twice before replying, because I had assumed the opposite. Off-target structures: if the sequence synthesis goes wrong, a completely different amino…
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #32 · Practice › Storage & stability · 3 Feb 2026 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Coming back to: Reading a supplier's product description as a marketing document Started this topic · Compounds › Other compounds · 17 Jan 2026 · 24 likes Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN…
-
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #50 · Pharmacology › Pharmacokinetics · 1 Jan 2026 · 13 likes post #49 answers the question as asked. The question underneath it is different. Individual variation: people vary in how quickly they absorb, distribute, metabolise,…
-
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #29 · Practice › Side effects · 27 Dec 2025 · 0 likes Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious…
-
Request: export my own posts — one year on Replied, post #21 · Meta › Feature requests · 11 Dec 2025 · 1 like I read post #19 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
Adjudicated events and why the definition matters Started this topic · Evidence › Trials · 11 Dec 2025 · 17 likes On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022).…
-
Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #3 · Compounds › Tirzepatide · 8 Dec 2025 · 4 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #58 · Compounds › Semaglutide · 30 Nov 2025 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Tracking that stops updating and then resumes — the long version Replied, post #44 · Sourcing › Logistics · 28 Nov 2025 · 3 likes Customs holds: if a parcel is held at customs and you can contact customs directly, declaring your personal use and providing documentation (order, labelling) can help.…
-
Thyroid function tests during substantial weight change Replied, post #148 · Clinical › Bloodwork · 25 Nov 2025 · 23 likes Lipid panel interpretation: total, LDL, HDL, triglycerides all on one panel. Reading them together is more informative than reading one value in isolation. An elevated…
-
[2026 update] What steady state means for the decision to escalate Replied, post #88 · Practice › Dosing & titration · 14 Nov 2025 · 1 like Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
-
About the Prescriber conversations category Replied, post #11 · Clinical › Prescriber conversations · 19 Oct 2025 · 0 likes Discussing side effects: be specific. "Nausea" is less useful than "I have nausea worst 24 to 36 hours after injection, severity 2 to 3 out of 4, stable over weeks".…
-
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #9 · Compounds › Oral incretins · 18 Oct 2025 · 26 likes On post #5 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #52 · Pharmacology › Receptor biology · 14 Oct 2025 · 1 like Coming back to post #50, because the follow-up matters more than the original answer. Species differences: rodent studies show the same compounds produce effects in…
-
What a purity-only report leaves out Replied, post #39 · Sourcing › Independent verification · 8 Oct 2025 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
A preprint whose numbers changed substantially at publication Replied, post #58 · Evidence › Preprints · 18 Sep 2025 · 0 likes Worth separating two things that post #54 runs together. Check whether it was later published: searching for the preprint's first author and keywords in PubMed might…
-
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #49 · Analytics › Method validation · 14 Sep 2025 · 2 likes post #48 is right about the mechanism and I think understates the practical bit. Limits of detection and quantitation: LOD is the lowest concentration that produces a…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #60 · Evidence › Journal club · 30 Aug 2025 · 3 likes SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the cardiovascular evidence to the oral formulation. Note that oral bioavailability is lower…
-
EU-wide position versus national implementation Replied, post #25 · Regional › European Union · 12 Aug 2025 · 8 likes Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires…
-
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #9 · Evidence › Journal club · 9 Aug 2025 · 0 likes post #8 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #41 · Compounds › Retatrutide · 9 Aug 2025 · 30 likes post #40 is right about the mechanism and I think understates the practical bit. Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is…
-
Travel coolers and how long they really hold Replied, post #85 · Devices › Cold chain · 8 Aug 2025 · 0 likes This follows post #82 rather than contradicting it. Shipment during summer or to hot climates: consider shipping to a cold-storage facility rather than to home if…
-
An emergency department visit, described afterwards Replied, post #51 · Safety › Adverse events · 7 Aug 2025 · 0 likes post #50 answers the question as asked. The question underneath it is different. Reporting to regulatory agencies: if you have had a serious event, reporting it to the…
-
Revisiting: List price versus negotiated price versus what you pay Replied, post #9 · Access › Pricing · 5 Aug 2025 · 7 likes Coming back to post #7, because the follow-up matters more than the original answer. Discount programmes and coupons: manufacturers often offer coupons that reduce…
-
How to research a compound with no human data without deceiving yourself Replied, post #82 · Compounds › Other compounds · 3 Aug 2025 · 19 likes How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from…
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #62 · Sourcing › Regulatory · 28 Jul 2025 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Revisiting: Filter needles: when they help and what they cost you Replied, post #39 · Devices › Syringes & needles · 24 Jul 2025 · 1 like post #38 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…
-
System suitability injections: if they failed, the run did not happen Replied, post #15 · Analytics › HPLC & UHPLC · 17 Jul 2025 · 8 likes Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and higher efficiency than larger particles (3.5 μm or 5 μm), at the cost of…
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #87 · Compounds › Tirzepatide · 13 Jul 2025 · 0 likes SURMOUNT-OSA is notable because it used an objective physiological endpoint, the apnoea-hypopnoea index, rather than a symptom scale. Two parallel trials, with and…
-
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #42 · Compounds › Cagrilintide & amylin analogues · 10 Jul 2025 · 3 likes Worth separating two things that post #38 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
Journal club: SURMOUNT-1, read without the press release Replied, post #154 · Evidence › Journal club · 8 Jul 2025 · 9 likes post #153 answers the question as asked. The question underneath it is different. TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed…
-
Reconstituting a multi-strength kit without mixing yourself up Replied, post #90 · Practice › Reconstitution · 24 Jun 2025 · 21 likes This follows post #87 rather than contradicting it. A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some preservatives…
-
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #48 · Compounds › Repair & healing peptides · 23 Jun 2025 · 31 likes The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and…
-
Coming back to: Why quantitation is the hard part, not detection Replied, post #28 · Analytics › Home & field testing · 18 Jun 2025 · 32 likes Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide…
-
Distinguishing a deletion sequence by mass alone — the long version Replied, post #25 · Analytics › Mass spectrometry · 6 Jun 2025 · 2 likes post #24 is right about the mechanism and I think understates the practical bit. Mass accuracy is expressed in parts per million. It is the difference between observed…
-
Half-life, steady state, and accumulation worked through Replied, post #23 · Pharmacology › Pharmacokinetics · 25 May 2025 · 14 likes Hepatic metabolism: the degree to which each compound is hepatically metabolised versus renally cleared is known but varies. Severe liver disease changes clearance.
-
Second pass at: Designing a personal experiment that could change your mind Replied, post #19 · Research Methods › N-of-1 designs · 18 May 2025 · 0 likes Designing a personal experiment that could actually change your mind: that is the standard for an n-of-1 design. An experiment designed so that any result confirms what…
-
A supplier that answers analytical questions with restated claims Replied, post #68 · Sourcing › Red flags · 2 May 2025 · 12 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Why cagrilintide alone is discussed so much less than in combination Replied, post #73 · Compounds › Cagrilintide & amylin analogues · 31 Mar 2025 · 15 likes Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The…
-
Follow-up: Journal club: the retatrutide phase 2 obesity paper Replied, post #8 · Evidence › Journal club · 21 Mar 2025 · 15 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Biased agonism: a real phenomenon, an over-used explanation Replied, post #108 · Pharmacology › Receptor biology · 16 Mar 2025 · 0 likes Picking up post #105: that is the part I would want checked first. Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those…
-
UK access routes, dated and sourced — a second dataset Replied, post #48 · Regional › UK & Ireland · 9 Mar 2025 · 3 likes Coming back to post #46, because the follow-up matters more than the original answer. Supply and shortage resilience: both UK and Ireland sourced primarily from…
-
Validating a method you did not develop — does this still hold? Replied, post #25 · Analytics › Method validation · 19 Feb 2025 · 12 likes On post #21 — agreed on the reasoning, with one qualification. Robustness: the method gives consistent results when minor parameters vary. Tested by deliberately…
-
Reading an MS report that only gives you a single number Replied, post #11 · Analytics › Mass spectrometry · 15 Feb 2025 · 8 likes On post #7 — agreed on the reasoning, with one qualification. Calibration matters: a high-resolution instrument out of calibration can report mass with ppm error large…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #92 · Compounds › Semaglutide · 25 Jan 2025 · 3 likes Picking up post #89: that is the part I would want checked first. Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they…
-
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #3 · Clinical › Bloodwork · 29 Dec 2024 · 2 likes Fasting state: some lab tests require fasting; others do not. Lipids on a fasting draw differ from lipids on a fed draw. Always note whether the test was fasting when…
-
Revisiting: What a well-designed human trial of a secretagogue would look like Started this topic · Compounds › Secretagogues & GH axis · 21 Dec 2024 · 3 likes On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic:…
-
Transit times by route, from a logged dataset — the long version Replied, post #39 · Sourcing › Logistics · 15 Dec 2024 · 5 likes Worth separating two things that post #35 runs together. Import restrictions by jurisdiction: what is legal to import for personal use varies enormously by country.…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #57 · Compounds › Repair & healing peptides · 15 Nov 2024 · 1 like BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #22 · Clinical › Prescriber conversations · 1 Nov 2024 · 1 like Coming back to post #20, because the follow-up matters more than the original answer. How to ask for what you need: rather than "should I take this", frame it as "I…
-
A vial that will not fully dissolve: what to check and in what order Replied, post #5 · Practice › Reconstitution · 28 Oct 2024 · 1 like I read post #3 twice before replying, because I had assumed the opposite. Reconstituting a multi-strength kit: if a kit contains 5 mg, 10 mg, 15 mg vials and you are…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #13 · Clinical › Bloodwork · 6 Sep 2024 · 0 likes post #12 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Correlation in a self-tracked dataset: what it can support Replied, post #55 · Research Methods › Statistics · 22 Aug 2024 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Coming back to: Purity assay versus content assay: two different numbers Replied, post #19 · Analytics › COA interpretation · 9 Aug 2024 · 1 like Purity and content are different measurements: purity tells you what proportion of the detected material is the intended species. Content tells you how much of the…
-
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #10 · Analytics › COA interpretation · 21 Jul 2024 · 11 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…